Invokana Sales Decline as Lawsuits Increase
Slowly, Type 2 diabetics and their families are becoming more aware of the dangers of SGLT2 inhibitors like Invokana. Recently, Johnson & Johnson, the manufacturer of Invokana released their 2017 First-Quarter Results. U.S. sales of Invokana fell by $50 million, which is almost 20%. Dangers of Invokana Invokana is the brand name of the drug canagliflozin,
Read More
Express Scripts Drops Onglyza Coverage over Safety Concerns
It should be troubling to all users of Onglyza and Kombiglyze XR that the largest pharmacy benefits manager in the United States, Express Scripts has dropped the Type 2 Diabetes medication. Express Scripts stated that the drug’s side effects were too concerning. Why is a corporation refusing to injury people, yet the FDA still won’t
Read More
Xarelto Trial Update: Week One Recap
The first week of the Xarelto trial (MDL No. 2592) in the U.S. District Court, Eastern District of Louisiana was a great first step for our clients to receive justice. Plaintiffs rested on Friday, and this week centers on the defense. About the Xarelto Trial Xarelto has been significantly responsible for numerous deaths and horrible side
Read More